Abraham I. Jacob
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Abraham I. Jacob has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Aryeh A. Frimer
The Department of Chemistry, Bar-Ilan University, Ramat Gan 5290002, Israel
1 shared publication - Ayelet Atkins
Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat Gan 5290002, Israel
1 shared publication - Carmit Alexenberg
The Department of Chemistry, Bar-Ilan University, Ramat Gan 5290002, Israel
1 shared publication - David Zitoun
Department of Chemistry, Bar-Ilan Institute of Nanotechnology and Advanced Materials (BINA), Bar-Ilan University, Ramat Gan 5290002, Israel
1 shared publication - Efrat Bodner
The Department of Chemistry, Bar-Ilan University, Ramat Gan 5290002, Israel
1 shared publication - Eli Varon
Bar-Ilan University
1 shared publication
Latest Publications
- Open Access
- 18 February 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (4) , 2286
An Engineered Nanocomplex with Photodynamic and Photothermal Synergistic Properties for Cancer Treatment
Photodynamic therapy (PDT) and photothermal therapy (PTT) are promising therapeutic methods for cancer treatment; however, as single modality therapies, either PDT or PTT is still limited in its success rate. A dual application of both PDT and PTT, in a combined protocol, has gained immense interest. In this study, gold nanoparticles (AuNPs) were conjugated with a PDT agent, meso-tetrahydroxyphenylchlorin (mTHPC) photosensitizer, designed as nanotherapeutic agents that can activate a dual photodynamic/photothermal therapy in SH-SY5Y human neuroblastoma cells. The AuNP-mTHPC complex is biocompatible, soluble, and photostable. PDT efficiency is high because of immediate reactive oxygen species (ROS) production upon mTHPC activation by the 650-nm laser, which decreased mitochondrial membrane potential (∆ψm). Likewise, the AuNP-mTHPC complex is used as a photoabsorbing (PTA) agent for PTT, due to efficient plasmon absorption and excellent photothermal conversion characteristics of AuNPs under laser irradiation at 532 nm. Under the laser irradiation of a PDT/PTT combination, a twofold phototoxicity outcome follows, compared to PDT-only or PTT-only treatment. This indicates that PDT and PTT have synergistic effects together as a combined therapeutic method. Our study aimed at applying the AuNP-mTHPC approach as a potential treatment of cancer in the biomedical field.
- 18 February 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (4) , 2286
Open AccessAn Engineered Nanocomplex with Photodynamic and Photothermal Synergistic Properties for Cancer Treatment
Photodynamic therapy (PDT) and photothermal therapy (PTT) are promising therapeutic methods for cancer treatment; however, as single modality therapies, either PDT or PTT is still limited in its success rate. A dual application of both PDT and PTT, in a combined protocol, has gained immense interest. In this study, gold nanoparticles (AuNPs) were conjugated with a PDT agent, meso-tetrahydroxyphenylchlorin (mTHPC) photosensitizer, designed as nanotherapeutic agents that can activate a dual photodynamic/photothermal therapy in SH-SY5Y human neuroblastoma cells. The AuNP-mTHPC complex is biocompatible, soluble, and photostable. PDT efficiency is high because of immediate reactive oxygen species (ROS) production upon mTHPC activation by the 650-nm laser, which decreased mitochondrial membrane potential (∆ψm). Likewise, the AuNP-mTHPC complex is used as a photoabsorbing (PTA) agent for PTT, due to efficient plasmon absorption and excellent photothermal conversion characteristics of AuNPs under laser irradiation at 532 nm. Under the laser irradiation of a PDT/PTT combination, a twofold phototoxicity outcome follows, compared to PDT-only or PTT-only treatment. This indicates that PDT and PTT have synergistic effects together as a combined therapeutic method. Our study aimed at applying the AuNP-mTHPC approach as a potential treatment of cancer in the biomedical field.